Marrow transplantation for patients with thalassemia: results in class 3 patients.
Thalassemia patients can be categorized as class 1 (minimal liver damage and iron overload), class 3 (extensive liver damage from iron overload), and class 2 (intermediate). These categories are prognostic for treatment outcome after marrow transplantation. Class 3 patients have more transplant-related mortality than other patients. This study examines transplantation outcome for class 3 patients. Records were reviewed of 215 patients in class 3 who received transplants in Pesaro from HLA-identical related donors between May 1, 1984 and May 1, 1994. The influence of pretransplant, peritransplant, and posttransplant variables on survival, relapse, and transplant-related mortality was examined by product-limit and proportional-hazards multivariate analysis. Age and conditioning regimen were influential on survival, and regimens with less than 200 mg/kg cyclosporine (CY) were associated with 5-year survival probabilities of .74 and .63 patients younger than 17 years and older patients, respectively. Transfusion history and regimen were influential on rejection with 5 year probabilities of .53 and .24 in patients who received less than or greater than 100 red blood cell transfusions before transplantation and regimens containing less than 200 mg/kg CY. Results of transplantation for patients with advanced thalassemia treatment have improved with the introduction of conditioning regimens with less CY. This has been associated with an increase in rejection (particularly in patients who have received < 100 red blood cell transfusions before transplant). Efforts at reducing the rejection rate by modifying the conditioning regimen should be concentrated on younger patients who have received a small number of transfusions. Patients with thalassemia who have HLA-identical family members should be transplanted before they are in class 3.
Lucarelli
G
G
Divisione Ematologica e Centro Trapianto Midollo Osseo di Muraglia, Pesaro, Italy.
Clift
R A
RA
Galimberti
M
M
Polchi
P
P
Angelucci
E
E
Baronciani
D
D
Giardini
C
C
Andreani
M
M
Manna
M
M
Nesci
S
S
Agostinelli
F
F
Rapa
S
S
Ripalti
M
M
Albertini
F
F
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000401:mortality; D002423:Cause of Death; D015913:Chelation Therapy; D002648:Child; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006084:Graft Rejection / Q000401:mortality; D006086:Graft vs Host Disease / Q000401:mortality; D006432:Hemochromatosis / Q000209:etiology / Q000473:pathology; D006801:Humans; D007558:Italy / Q000453:epidemiology; D015993:Life Tables; D008099:Liver / Q000473:pathology; D008107:Liver Diseases / Q000453:epidemiology / Q000209:etiology / Q000473:pathology; D008297:Male; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D012008:Recurrence; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013789:Thalassemia / Q000097:blood / Q000150:complications / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D065227:Transfusion Reaction; D016896:Treatment Outcome